{
    "clinical_study": {
        "@rank": "153293", 
        "brief_summary": {
            "textblock": "This is a study to determine whether albuterol or oxandrolone, alone or in combination, are\n      able to increase strength and muscle mass in patients with FSHD. It also will determine if\n      albuterol given in \"pulsed\" fashion will have more effect than when given continuously."
        }, 
        "brief_title": "Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)", 
        "completion_date": "August 2004", 
        "condition": "Muscular Dystrophies", 
        "condition_browse": {
            "mesh_term": [
                "Muscular Dystrophies", 
                "Muscular Dystrophy, Facioscapulohumeral"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients will be randomized to 1 of 4 groups: placebo, pulsed albuterol, oxandrolone, or\n      both pulsed albuterol and oxandrolone. Treatment will continue for 52 weeks unless\n      unacceptable side effects occur. Patients will undergo testing of muscle function. All\n      patients will return for follow-up assessments at Weeks 4, 12, 26, and 52."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Presence of 4q35 \"small fragment\" of less than 40 kb by standard DNA testing\n\n          -  Weakness of the facial muscles, including frontalis, orbicularis oculi, or\n             orbicularis oris\n\n          -  Weakness of scapular stabilizers or foot dorsiflexors\n\n          -  Ambulatory\n\n          -  Weakness grade 2 or worse in the arm using upper extremity grading scale\n\n        Exclusion criteria:\n\n          -  Prior use of oral beta-2 agonists for a period of at least 1 year or within the past\n             3 months\n\n          -  Concurrent use of other sympathomimetic agents, antidepressants, or beta-2 receptor\n             blockers\n\n          -  Pregnancy\n\n          -  Known hypersensitivity to anabolic steroids\n\n          -  Any medical or psychological condition that would interfere with the study\n\n          -  Requirement for a wheelchair"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "160", 
        "firstreceived_date": "December 5, 2001", 
        "id_info": {
            "nct_id": "NCT00027391", 
            "org_study_id": "FD-R-2029-01", 
            "secondary_id": "FD-R-002029-01"
        }, 
        "intervention": [
            {
                "intervention_name": "Albuterol", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Oxandrolone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Albuterol", 
                "Oxandrolone"
            ]
        }, 
        "keyword": "Muscle Weakness, Muscular Dystrophy", 
        "lastchanged_date": "January 31, 2006", 
        "location": {
            "facility": {
                "address": {
                    "city": "Columbus", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "43210"
                }, 
                "name": "Ohio State University Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Clinical Trials of Albuterol and Oxandrolone in FSH Dystrophy", 
        "overall_official": {
            "affiliation": "Ohio State University", 
            "last_name": "John T. Kissel, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00027391"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "September 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2001"
    }, 
    "geocoordinates": {
        "Ohio State University Medical Center": "39.961 -82.999"
    }
}